Tivdak
Seagen, Genmab’s Tivdak shows survival benefit in cervical cancer phase 3 trial
Anika Sharma
Amidst the Federal Trade Commission’s close scrutiny of Pfizer’s monumental $43 billion acquisition of Seagen, there’s a significant breakthrough in ...
